ZYPHORE THERAPEUTICS

What this means for you

Approved and waiting on proof of use. It will register unless the applicant drops it, and its 22 Aug 2025 filing date already counts against anyone who files later.

Record

Serial number

99352357

Mark type

Stylized text

Filed

22 Aug 2025

Published for opposition

24 Mar 2026

Attorney of record

Ava R. Shelby

Goods and services

• Class 001 — Chemicals: Enzyme preparations for use in the medical industry; enzyme stabilizers; enzyme substrates for scientific purposes.
• Class 005 — Pharmaceuticals: Enzymes for medical purposes; engineered enzymes for medical purposes; enzyme substrates for medical purposes; therapeutic pharmaceuticals for the treatment and prevention of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; pharmaceutical preparations for the treatment and prevention of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; drug delivery agents that facilitate delivery and efficacy of pharmaceuticals, namely, drug delivery agents consisting of enzymes that facilitate delivery of a wide range of pharmaceuticals; pharmaceutical and biological preparations for delivering therapeutic agents, namely, enzymes for the treatment of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; drug carriers for medical use, namely, drug delivery agents consisting of enzymes that facilitate the delivery of pharmaceutical preparations for delivering drugs to human cells, tissues and organs.
• Class 042 — Scientific and technological services: Providing medical and scientific research information in the fields of pharmaceuticals and biotechnology; drug discovery services; development of pharmaceutical and therapeutic preparations and medicines; research and development in the pharmaceutical and biotechnology fields, namely, research and development for the treatment of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes; research and development in the field of biotechnology; medical and scientific research in the field of autoimmune diseases, cardiovascular diseases, central nervous system diseases and disorders, endocrine disorders, gastrointestinal diseases, genitourinary diseases and disorders, genetic diseases and disorders, infectious diseases, inflammation-related diseases and disorders, kidney diseases, liver diseases, hepatological diseases, respiratory diseases, metabolic diseases and disorders, ophthalmic diseases, musculoskeletal disorders, rare muscle diseases, neurodegenerative diseases and disorders, neurological diseases and disorders, immune system diseases and disorders, neuromuscular and viral diseases and disorders, blood disorders, cardiopulmonary diseases and disorders, bone growth disorders, skin disorders and diseases, psychiatric disorders and diseases, sexual dysfunction, hormonal disorders, arthritis, cancer, hypertension, pain, stroke, obesity and diabetes.

Owner

• Zyphore Therapeutics, Inc., Boston, MA, US
• Zyphore Therapeutics, Inc., Boston, MA, US

Prosecution history

• 24 Mar 2026 — OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
• 24 Mar 2026 — PUBLISHED FOR OPPOSITION
• 18 Mar 2026 — NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
• 03 Mar 2026 — APPROVED FOR PUB - PRINCIPAL REGISTER
• 03 Mar 2026 — EXAMINER'S AMENDMENT ENTERED
• 03 Mar 2026 — NOTIFICATION OF EXAMINERS AMENDMENT E-MAILED
• 03 Mar 2026 — EXAMINERS AMENDMENT E-MAILED
• 03 Mar 2026 — EXAMINERS AMENDMENT -WRITTEN
• 14 Jan 2026 — NOTIFICATION OF NON-FINAL ACTION E-MAILED
• 14 Jan 2026 — NON-FINAL ACTION E-MAILED
• 14 Jan 2026 — NON-FINAL ACTION WRITTEN
• 07 Jan 2026 — ASSIGNED TO EXAMINER
• 24 Aug 2025 — NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
• 22 Aug 2025 — APPLICATION FILING RECEIPT MAILED
• 22 Aug 2025 — NEW APPLICATION ENTERED